Advertisement

U.S. markets closed

S&P Futures
5,913.00
+7.00(+0.12%)
Dow Futures
43,571.00
+53.00(+0.12%)
Nasdaq Futures
20,511.50
+28.00(+0.14%)
Russell 2000 Futures
2,296.50
+5.30(+0.23%)
Crude Oil
69.49
+0.27(+0.39%)
Gold
2,736.70
+6.70(+0.25%)

Clarity Pharmaceuticals Ltd (CLRPF)

OTC Markets OTCPK - OTC Markets OTCPK Delayed Price. Currency in USD

4.5520

0.0000

(0.00%)

At close: 04:00PM EDT

Loading interactive chart...

PR Newswire
Copper-67 SAR-bisPSMA updates
Copper-67 SAR-bisPSMA updates
PR Newswire
Positive guidance from the U.S. FDA on 64Cu-SAR-bisPSMA Phase III trial in patients with recurrence of prostate cancer
Clarity Pharmaceuticals (ASX: CU6) ("Clarity", "the Company"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce it will be commencing a pivotal Phase III trial of its 64Cu-SAR-bisPSMA diagnostic in patients with BCR of prostate cancer following a successful end of phase meeting with the U.S. FDA. The trial, named AMPLIFY (64Cu-SAR-bisPSMA Positron Emission To